TORONTO, June 11, 2019 /CNW/ - 01 Communique
Laboratory Inc. (the "Company") (ONE:TSX-V) today reported results
for its second quarter of fiscal 2019, ended April 30, 2019. The loss for the quarter was
$196,043 (2018 - $35,044) an increase of $160,999 a direct result of the investment the
Company has made in developing its Post-Quantum Cryptography
("PQ-Crypto") technology and getting ready for the commercial
launch of the first of many products incorporating this technology,
IronCAP X, this coming September. The Company has completed the
period with $462,026 of cash and cash
equivalents and a guaranteed investment
certificate.
"We have come a long way over the past several months as we get
ready for the commercial launch of IronCAP X in September," said
Andrew Cheung, President and CEO for
01 Communique. "We filed a patent application in the United States relating to our
cryptographic systems and methods in January. We added several new
members to our development team with expertise in security. We
demonstrated our new product at our shareholders' meeting in April.
We completed a new web site, which will be up and running shorty.
We initiated discussion with a number of key partners in the
security space. We are in the midst of putting together a sales and
marketing team. With all of this on the go and more to come we have
enlisted a leading investment firm to complete a non-brokered
private placement."
Highlights:
- Major milestones have already been achieved as the Company gets
ready for commercial availability of IronCAP X, which include:
-
- Filing a patent application in the
United States for this unique new technology.
- Moving forward with the memorandum of understanding signed with
Hitachi Solutions Create, Ltd. to undertake a market feasibility
study in Japan with respect to the
Company's new technology.
- Successful demonstration of IronCAP X in April at the Company's
shareholders meeting.
- Assembled the basis of a world class development team tasked
with completion of IronCAP X for this September.
- Added new members to the board of directors and its advisory
committee with significant expertise in blockchain technology and
security.
- Developed an impressive product road map that encompasses a
number of new products incorporating the Company's PQ-Crypto
technology planned for development after the release of IronCAP
X.
- Getting ready for the September launch:
-
- The Company's new IronCAP web site (www.ironcap.ca) is
planned to go live later this month. The redesigned web site offers
quick and intuitive access to critical information regarding the
IronCAP technology and family of products including IronCAP X and
offers a significantly improved user experience.
- The new web site provides IronCAP X beta users the ability to
register for a trial of IronCAP X when it is available.
- The Company is in advanced stages of discussion with an
experienced sales and marketing person to lead the launch of
IronCAP X.
- Business development meetings are progressing with several
leading technology firms with respect to licensing IronCAP Crypto
(ICC) and IronCAP X.
- The Company plans to launch its IronCAP API in July to allow
potential integrators to beta test ICC integration with their
products.
- Strengthening the balance sheet:
-
- To effectively launch IronCAP X and bring on board experienced
sales and marketing personnel, the Company has enlisted a leading
investment firm to assist the Company with the completion of a
non-brokered private placement. The terms of the financing will be
determined in the context of the market for the Company's common
shares.
- The Company's Debenture contains an expiry acceleration clause
which was amended to extend the expiration date of the associated
warrants such that the exercise period of the warrants after the
amendment is now September 10, 2019
(prior to the amendment it was June 12,
2019).
"With everything we have on the go as we head into the countdown
for the commercial launch of IronCAP X we believe it is important
for us to strengthen our balance sheet," said Andrew Cheung. "As such we are moving forward
with the above referenced non-brokered private placement with
expectations of raising up to $1,500,000 of working capital which we believe
will be sufficient for us to attract the personnel we require and
complete a successful launch. I am extremely excited about the
prospect for the future of our Company."
Conference Call Information:
01 Communique will host a live teleconference allowing for
questions and answers on Wednesday June 12,
2019 at 10:00AM EST to discuss
the Company's quarterly results as well as providing an update on
the outlook for the future with the upcoming release of the
Company's new product IronCAP X.
Teleconference details:
Wednesday June 12th at 10:00 AM
Dial in
Numbers:
Local (416) 507-1616
Toll free
1-866-279-1594
Pass code when prompted is
835084
About IronCAP X:
IronCAP X is the Company's first product to incorporate its
patent pending ICC technology and is believed to be the world's
first quantum-safe email system. The system demonstrated at the
Company's shareholder meeting showed how easy it is to send and
receive an email that encapsulates 01's encryption and digital
signing system, IronCAP X, providing an end-to-end encrypted
message that only the recipient can decrypt and read. The Company
reiterated that it is on track for a commercial release of IronCAP
X this coming September.
About 01 Communique
Established in 1992, 01 Communique Laboratory Inc. (TSX-V: ONE)
has always been at the forefront of technology. The Company's
legacy business provides its customers with a suite of secure
remote access services and products. In early 2018 the Company
began transitioning its business focusing on cybersecurity with the
development and implementation of Post-Quantum Cryptography and
Post-Quantum Blockchain technologies, which can be implemented on
classical computer systems as we know them today while at the same
time intended to be secure enough to safeguard against potential
Quantum Computer attacks. The Company's legacy products are
protected in the U.S.A. by its
patents #6,928,479 / #6,938,076 / #8,234,701; in Canada by its patents #2,309,398 / #2,524,039
and in Japan by its patent
#4,875,094. For more information, visit the Company's web site at
www.01com.com
Cautionary Note Regarding Forward-looking Statements.
Certain statements in this news release may constitute
"forward-looking" statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. When used in this news release, such statements use
such words as "may", "will", "expect", "believe", "plan", "intend",
"are confident" and other similar terminology. Such statements
include statements regarding the timing of the release of IronCAP
X, the future of quantum computers and their impact on the
Company's product offering, the functionality of the Company's
products and the intended product lines for the Company's
technology, the execution of a memorandum of understanding signed
with Hitachi Solutions Create, Ltd., the potential licensing of the
Company's technology and the ability to close the proposed
financing. These statements reflect current expectations regarding
future events and operating performance and speak only as of the
date of this news release. Forward-looking statements involve
significant risks and uncertainties, should not be read as
guarantees of future performance or results, and will not
necessarily be accurate indications of whether or not such results
will be achieved. A number of factors could cause actual results to
differ materially from the results discussed in the forward-looking
statements, including, but not limited to, the factors discussed
under "Risk and Uncertainties" in the Company's Management`s
Discussion and Analysis document filed on SEDAR. Although the
forward-looking statements contained in this news release are based
upon what management of the Company believes are reasonable
assumptions, the Company cannot assure investors that actual
results will be consistent with these forward looking statements.
These forward-looking statements are made as of the date of this
news release, and the Company assumes no obligation to update or
revise them to reflect new events or circumstances.
Neither TSX Venture Exchange ("TSX-V") nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
01 Communique
Laboratory Inc. SELECTED FINANCIAL
INFORMATION Interim Consolidated Statements of Financial
Position (Unaudited) As at April 30, 2019 and
December 31, 2018
|
|
|
|
|
|
30-Apr-19
|
|
31-Oct-18
|
|
|
|
|
Assets
|
|
|
|
Current
assets
|
|
|
|
|
Cash and cash
equivalents
|
$
|
112,026
|
|
$
|
113,760
|
|
Guaranteed investment
certificate
|
350,000
|
|
700,000
|
|
Accounts
receivable
|
55,988
|
|
62,696
|
|
Prepaid expenses and
other assets
|
22,830
|
|
6,275
|
|
540,844
|
|
882,731
|
|
|
|
|
Plant and
equipment
|
18,634
|
|
16,085
|
|
$
|
559,478
|
|
$
|
898,816
|
|
|
|
|
Liabilities &
Shareholders' Deficit
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
Accounts payable and
accrued liabilities
|
$
|
534,765
|
|
$
|
584,552
|
|
Deferred
revenue
|
9,463
|
|
8,455
|
|
Liability component
of debenture
|
383,917
|
|
390,733
|
|
928,145
|
|
983,740
|
|
|
|
|
Shareholders'
equity
|
|
|
|
|
Share
capital
|
41,186,529
|
|
41,186,529
|
|
Contributed
surplus
|
5,548,217
|
|
5,464,721
|
|
Share purchase
warrants
|
400,000
|
|
400,000
|
|
Agent compensation
options
|
99,200
|
|
99,200
|
|
Equity portion of
Debenture
|
80,924
|
|
64,811
|
|
Deficit
|
(47,683,537)
|
|
(47,300,185)
|
|
(368,667)
|
|
(84,924)
|
Total liabilities and
shareholders' deficit
|
$
|
559,478
|
|
$
|
898,816
|
01 Communique
Laboratory Inc. SELECTED FINANCIAL
INFORMATION Interim Consolidated Statements of Operations
and Comprehensive Income (Unaudited) For the 3
and 6 month periods ended April 30, 2019 and 2018|
|
|
|
|
|
|
three months
ending
|
|
six months
ending
|
|
30-Apr-19
|
30-Apr-18
|
|
30-Apr-19
|
30-Apr-18
|
|
|
|
|
|
|
Revenue
|
$
74,685
|
$
73,809
|
|
$
124,720
|
$
108,653
|
|
|
|
|
|
|
Expenses
(income):
|
|
|
|
|
|
Selling, general and
administrative
|
151,137
|
55,566
|
|
281,149
|
90,041
|
Research and
development
|
94,930
|
35,168
|
|
179,178
|
58,942
|
Interest
|
(1,913)
|
(10)
|
|
(2,710)
|
(18)
|
|
244,153
|
90,724
|
|
457,617
|
148,965
|
Loss before interest
and accretion on
|
|
|
|
|
|
liability component
of debenture and taxes
|
(169,468)
|
(16,915)
|
|
(332,897)
|
(40,312)
|
|
|
|
|
|
|
Interest on
debenture
|
15,000
|
10,295
|
|
30,000
|
20,295
|
Accretion on
liability portion of debenture
|
4,762
|
-
|
|
9,297
|
8,420
|
(Loss) before
taxes
|
(189,230)
|
(27,210)
|
|
(372,194)
|
(69,027)
|
|
|
|
|
|
|
Withholding
taxes
|
6,813
|
7,834
|
|
11,158
|
10,554
|
(Loss) for the period
and comprehensive loss
|
$
(196,043)
|
$
(35,044)
|
|
$
(383,352)
|
$
(79,581)
|
|
|
|
|
|
|
Basic
|
$
(0.00)
|
$
(0.00)
|
|
$
(0.00)
|
$
(0.00)
|
Diluted
|
$
(0.00)
|
$
(0.00)
|
|
$
(0.00)
|
$
(0.00)
|
|
|
|
|
|
|
Weighted average
number of common shares
|
|
|
|
|
|
Basic
|
76,543,807
|
66,543,807
|
|
76,543,807
|
66,543,807
|
Diluted
|
76,543,807
|
66,543,807
|
|
76,543,807
|
66,543,807
|
01 Communique
Laboratory Inc. SELECTED FINANCIAL
INFORMATION Interim Consolidated Statements of Cash
Flows (Unaudited) For the 3 and 6 month periods
ended April 30, 2019 and 2018
|
|
|
|
|
|
|
three months
ending
|
|
six months
ending
|
|
|
30-Apr-19
|
30-Apr-18
|
|
30-Apr-19
|
30-Apr-18
|
Cash provided by
(used in):
|
|
|
|
|
|
|
|
|
|
|
|
Operating
activities:
|
|
|
|
|
|
Income (Loss) for the
period
|
$
(196,043)
|
$
(35,044)
|
|
$
(383,352)
|
$
(79,581)
|
Adjustments to
reconcile the loss for
|
|
|
|
|
|
the period to
net cash flows from operating activities:
|
|
|
|
|
|
Depreciation
|
1,294
|
340
|
|
2,696
|
783
|
Stock-based
compensation
|
44,550
|
5,000
|
|
83,496
|
10,915
|
Accretion on liability
portion of debenture
|
4,762
|
-
|
|
9,297
|
8,420
|
Interest
income
|
(1,913)
|
(10)
|
|
(2,710)
|
(18)
|
Change in non-cash
working capital
|
(986)
|
(2,781)
|
|
(58,626)
|
(34,519)
|
|
(148,336)
|
(32,495)
|
|
(349,199)
|
(94,000)
|
Interest income
received
|
1,913
|
10
|
|
2,710
|
18
|
|
(146,423)
|
(32,485)
|
|
(346,489)
|
(93,982)
|
|
|
|
|
|
|
Financing
activities:
|
|
|
|
|
|
Proceeds from
guaranteed investment certificate
|
200,000
|
|
|
350,000
|
|
Purchase of capital
assets
|
(3,845)
|
(635)
|
|
(5,245)
|
(2,395)
|
Increase (decrease) in
cash
|
49,732
|
(33,120)
|
|
(1,734)
|
(96,377)
|
|
|
|
|
|
|
Cash and cash
equivalents, beginning of period
|
62,294
|
175,319
|
|
113,760
|
238,576
|
Cash and cash
equivalents, end of period
|
$
112,026
|
$
142,199
|
|
$
112,026
|
$
142,199
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents comprise:
|
|
|
|
|
|
Demand
deposits
|
$
350,000
|
$
-
|
|
|
|
Cash
|
112,026
|
142,199
|
|
|
|
|
$
462,026
|
$
142,199
|
|
|
|
SOURCE 01 Communique Laboratory Inc.